Attralus
Attralus develops novel pan-amyloid removal therapeutics and diagnostic imaging agents for systemic amyloidosis and neurodegenerative diseases.
Services
Attralus specializes in developing novel pan-amyloid removal (PAR) therapeutics that target and eliminate toxic amyloid deposits. Their suite of services includes the creation of biologics designed for systemic amyloidosis treatment at all stages. Additionally, Attralus offers diagnostics for amyloidosis using their proprietary imaging agents specific to this condition.
Products
Attralus' leading therapeutic product, AT-02, is a humanized IgG1 monoclonal antibody fused with a pan-amyloid binding peptide. Currently in Phase 1/2 development, AT-02 targets ATTR and AL amyloidosis. The company's diagnostic product, AT-01 (I-124-Evuzamitide), is under clinical investigation for detecting amyloid in the entire body and has demonstrated high sensitivity in detecting cardiac amyloidosis. Attralus is also developing AT-05, a pan-amyloid diagnostic imaging agent labeled with technetium-99m (Tc-99m).
Technology
Attralus utilizes proprietary technology to develop biologics and diagnostic tools specifically aimed at amyloidosis. Their groundbreaking amyloidosis-specific diagnostic imaging agent sets them apart in the field. AT-01 has shown promising results in detecting various amyloid deposits in major organs and may offer higher sensitivity compared to traditional diagnostic methods like 99m-Tc pyrophosphate bone scintigraphy.
History
Attralus has made significant strides in the field of amyloidosis treatment and diagnostics. The company recently closed a $56 million financing round led by Alpha Wave Ventures and Bristol Myers Squibb. This funding is expected to advance their pipeline of innovative therapeutics and diagnostics, including the ongoing development of their lead product, AT-02, and the clinical investigation of AT-01 for whole-body amyloid detection.
Clinical Research
Attralus is actively involved in clinical research to verify the efficacy of their diagnostic and therapeutic products. AT-01 has shown 100% sensitivity in detecting cardiac amyloidosis across three independent studies and may be more sensitive than existing diagnostic methods. Additionally, AT-01's uptake in cardiac amyloidosis correlates significantly with traditional cardiac function measures, suggesting its potential in monitoring organ-specific amyloid load.